NASDAQ:ZLAB - Zai Lab Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $29.38 +0.70 (+2.44 %) (As of 04/19/2019 04:00 PM ET)Previous Close$29.38Today's Range$28.3110 - $29.4352-Week Range$14.29 - $33.86Volume116,857 shsAverage Volume163,645 shsMarket Capitalization$1.71 billionP/E RatioN/ADividend YieldN/ABeta1.22 ProfileDiscussionAnalyst RatingsChartFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China. Receive ZLAB News and Ratings via Email Sign-up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZLAB Previous Symbol CUSIPN/A CIK1704292 Webwww.zailaboratory.com Phone86-21-6163-2588Debt Debt-to-Equity RatioN/A Current Ratio5.51 Quick Ratio5.51Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$130,000.00 Price / Sales13,131.73 Cash FlowN/A Price / Cash FlowN/A Book Value$4.32 per share Price / Book6.80Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees448 Outstanding Shares58,105,000Market Cap$1.71 billion Next Earnings DateN/A OptionableOptionable Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions What is Zai Lab's stock symbol? Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB." What price target have analysts set for ZLAB? 3 brokers have issued 12 month target prices for Zai Lab's stock. Their predictions range from $34.70 to $43.00. On average, they anticipate Zai Lab's share price to reach $38.85 in the next twelve months. This suggests a possible upside of 32.2% from the stock's current price. View Analyst Price Targets for Zai Lab. What is the consensus analysts' recommendation for Zai Lab? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zai Lab. Has Zai Lab been receiving favorable news coverage? Media stories about ZLAB stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zai Lab earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. Who are some of Zai Lab's key competitors? Some companies that are related to Zai Lab include Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Nektar Therapeutics (NKTR), Alkermes (ALKS), Patheon (PTHN), Array Biopharma (ARRY), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), TESARO (TSRO) and Taro Pharmaceutical Industries (TARO). What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include Crispr Therapeutics (CRSP), Portola Pharmaceuticals (PTLA), Rigel Pharmaceuticals (RIGL), Fate Therapeutics (FATE), Celgene (CELG), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Nektar Therapeutics (NKTR), Spark Therapeutics (ONCE) and Viking Therapeutics (VKTX). Who are Zai Lab's key executives? Zai Lab's management team includes the folowing people: Dr. Ying Du, Founder, Chairman & CEO (Age 53)Mr. Tao Fu, Pres, COO & Director (Age 47)Mr. Ki Chul Cho, Chief Financial Officer (Age 41)Dr. Ning Xu, Exec. VP of Clinical Operations & Regulatory Affairs (Age 54)Dr. Qi Liu, Chief Medical Officer of Oncology (Age 54) When did Zai Lab IPO? (ZLAB) raised $100 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO. Who are Zai Lab's major shareholders? Zai Lab's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Segantii Capital Management Ltd (4.14%) and Tree Line Advisors Hong Kong Ltd. (0.90%). Which institutional investors are buying Zai Lab stock? ZLAB stock was acquired by a variety of institutional investors in the last quarter, including Tree Line Advisors Hong Kong Ltd. and Segantii Capital Management Ltd. How do I buy shares of Zai Lab? Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Zai Lab's stock price today? One share of ZLAB stock can currently be purchased for approximately $29.38. How big of a company is Zai Lab? Zai Lab has a market capitalization of $1.71 billion and generates $130,000.00 in revenue each year. The company earns $-139,070,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. Zai Lab employs 448 workers across the globe. What is Zai Lab's official website? The official website for Zai Lab is http://www.zailaboratory.com. How can I contact Zai Lab? Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected] MarketBeat Community Rating for Zai Lab (NASDAQ ZLAB)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 129 (Vote Outperform)Underperform Votes: 163 (Vote Underperform)Total Votes: 292MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote "Outperform" if you believe ZLAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/20/2019 by MarketBeat.com StaffFeatured Article: What is a Market Correction?